{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:17:28Z","timestamp":1775683048965,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T00:00:00Z","timestamp":1424908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s10067-015-2902-5","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T01:08:23Z","timestamp":1424826503000},"page":"1327-1331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Early systemic sclerosis\u2014opportunities for treatment"],"prefix":"10.1007","volume":"34","author":[{"given":"Lazaros I.","family":"Sakkas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodora","family":"Simopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Katsiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Bogdanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian C.","family":"Chikanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,26]]},"reference":[{"key":"2902_CR1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","volume":"71","author":"FM Meier","year":"2012","unstructured":"Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355\u20131360","journal-title":"Ann Rheum Dis"},{"key":"2902_CR2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/ard.2008.094193","volume":"69","author":"L Mouthon","year":"2010","unstructured":"Mouthon L, Mestre-Stanislas C, Berezne A, Rannou F, Guilpain P, Revel M et al (2010) Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 69:214\u2013217","journal-title":"Ann Rheum Dis"},{"key":"2902_CR3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/rheumatology\/kes429","volume":"52","author":"E Savarino","year":"2013","unstructured":"Savarino E, Mei F, Parodi A, Ghio M, Furnari M, Gentile A et al (2013) Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford) 52:1095\u20131100","journal-title":"Rheumatology (Oxford)"},{"key":"2902_CR4","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","volume":"43","author":"VD Steen","year":"2000","unstructured":"Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437\u20132444","journal-title":"Arthritis Rheum"},{"key":"2902_CR5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.200912-1820OC","volume":"182","author":"A Campo","year":"2010","unstructured":"Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D et al (2010) Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 182:252\u2013260","journal-title":"Am J Respir Crit Care Med"},{"key":"2902_CR6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809\u20131815","journal-title":"Ann Rheum Dis"},{"key":"2902_CR7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","volume":"51","author":"L Guillevin","year":"2012","unstructured":"Guillevin L, Berezne A, Seror R, Teixeira L, Pourrat J, Mahr A et al (2012) Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 51:460\u2013467","journal-title":"Rheumatology (Oxford)"},{"key":"2902_CR8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/BOR.0000000000000027","volume":"26","author":"M Nikpour","year":"2014","unstructured":"Nikpour M, Baron M (2014) Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 26:131\u2013137","journal-title":"Curr Opin Rheumatol"},{"key":"2902_CR9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.09-0108","volume":"136","author":"J Goldin","year":"2009","unstructured":"Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D et al (2009) Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 136:1333\u20131340","journal-title":"Chest"},{"key":"2902_CR10","first-page":"RA187","volume":"16","author":"K Broad","year":"2010","unstructured":"Broad K, Pope JE (2010) The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Med Sci Monit 16:RA187\u2013RA190","journal-title":"Med Sci Monit"},{"key":"2902_CR11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","volume":"133","author":"AJ Gerbino","year":"2008","unstructured":"Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133:455\u2013460","journal-title":"Chest"},{"key":"2902_CR12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10067-010-1498-z","volume":"29","author":"A Koutroumpas","year":"2010","unstructured":"Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI (2010) Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 29:1167\u20131168","journal-title":"Clin Rheumatol"},{"key":"2902_CR13","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2010.142000","volume":"70","author":"EN Le","year":"2011","unstructured":"Le EN, Wigley FM, Shah AA, Boin F, Hummers LK (2011) Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70:1104\u20131107","journal-title":"Ann Rheum Dis"},{"key":"2902_CR14","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3899\/jrheum.111229","volume":"39","author":"FA Mendoza","year":"2012","unstructured":"Mendoza FA, Nagle SJ, Lee JB, Jimenez SA (2012) A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39:1241\u20131247","journal-title":"J Rheumatol"},{"key":"2902_CR15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/rheumatology\/kep398","volume":"49","author":"D Launay","year":"2010","unstructured":"Launay D, Sitbon O, Le Pavec J, Savale L, Tcherakian C, Yaici A et al (2010) Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 49:490\u2013500","journal-title":"Rheumatology (Oxford)"},{"key":"2902_CR16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C et al (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49:271\u2013280","journal-title":"Rheumatology (Oxford)"},{"key":"2902_CR17","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","volume":"12","author":"S Bosello","year":"2010","unstructured":"Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B et al (2010) B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 12:R54","journal-title":"Arthritis Res Ther"},{"key":"2902_CR18","author":"S Jordan","year":"2014","unstructured":"Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y et al (2014) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. doi: 10.1136\/annrheumdis-2013-204522","journal-title":"Ann Rheum Dis"},{"key":"2902_CR19","doi-asserted-by":"crossref","unstructured":"(1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581\u2013590","DOI":"10.1002\/art.1780230510"},{"key":"2902_CR20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2014.53","volume":"10","author":"YY Ho","year":"2014","unstructured":"Ho YY, Lagares D, Tager AM, Kapoor M (2014) Fibrosis\u2014a lethal component of systemic sclerosis. Nat Rev Rheumatol 10:390\u2013402","journal-title":"Nat Rev Rheumatol"},{"key":"2902_CR21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ncprheum0346","volume":"2","author":"LI Sakkas","year":"2006","unstructured":"Sakkas LI, Chikanza IC, Platsoucas CD (2006) Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2:679\u2013685","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2902_CR22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature12614","volume":"503","author":"EE Gerber","year":"2013","unstructured":"Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, Huso DL et al (2013) Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 503:126\u2013130","journal-title":"Nature"},{"key":"2902_CR23","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","volume":"58","author":"M Koenig","year":"2008","unstructured":"Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58:3902\u20133912","journal-title":"Arthritis Rheum"},{"key":"2902_CR24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2133.1992.tb00100.x","volume":"126","author":"AJ Freemont","year":"1992","unstructured":"Freemont AJ, Hoyland J, Fielding P, Hodson N, Jayson MI (1992) Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 126:561\u2013568","journal-title":"Br J Dermatol"},{"key":"2902_CR25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1711660307","volume":"166","author":"RJ Prescott","year":"1992","unstructured":"Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255\u2013263","journal-title":"J Pathol"},{"key":"2902_CR26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/art.1780220205","volume":"22","author":"GP Rodnan","year":"1979","unstructured":"Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22:130\u2013140","journal-title":"Arthritis Rheum"},{"key":"2902_CR27","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.4049\/jimmunol.168.7.3649","volume":"168","author":"LI Sakkas","year":"2002","unstructured":"Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168:3649\u20133659","journal-title":"J Immunol"},{"key":"2902_CR28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","volume":"51","author":"S O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly S, Hugle T, van Laar JM (2012) T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 51:1540\u20131549","journal-title":"Rheumatology (Oxford)"},{"key":"2902_CR29","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1186\/ar4334","volume":"15","author":"NC Brembilla","year":"2013","unstructured":"Brembilla NC, Montanari E, Truchetet ME, Raschi E, Meroni P, Chizzolini C (2013) Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther 15:R151","journal-title":"Arthritis Res Ther"},{"key":"2902_CR30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.21646","volume":"54","author":"J Henault","year":"2006","unstructured":"Henault J, Robitaille G, Senecal JL, Raymond Y (2006) DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54:963\u2013973","journal-title":"Arthritis Rheum"},{"key":"2902_CR31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.2353\/ajpath.2007.060649","volume":"170","author":"EM Pierce","year":"2007","unstructured":"Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Flaherty KR, Martinez FJ et al (2007) Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am J Pathol 170:1152\u20131164","journal-title":"Am J Pathol"},{"key":"2902_CR32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2249.2004.02615.x","volume":"138","author":"C Nishijima","year":"2004","unstructured":"Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K et al (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138:357\u2013363","journal-title":"Clin Exp Immunol"},{"key":"2902_CR33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2249.2009.04059.x","volume":"159","author":"M Odaka","year":"2010","unstructured":"Odaka M, Hasegawa M, Hamaguchi Y, Ishiura N, Kumada S, Matsushita T et al (2010) Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clin Exp Immunol 159:176\u2013184","journal-title":"Clin Exp Immunol"},{"key":"2902_CR34","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","volume":"354","author":"SS Baroni","year":"2006","unstructured":"Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667\u20132676","journal-title":"N Engl J Med"},{"key":"2902_CR35","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.24381","volume":"60","author":"JF Classen","year":"2009","unstructured":"Classen JF, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikstrom G et al (2009) Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 60:1137\u20131144","journal-title":"Arthritis Rheum"},{"key":"2902_CR36","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.24365","volume":"60","author":"N Loizos","year":"2009","unstructured":"Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L et al (2009) Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 60:1145\u20131151","journal-title":"Arthritis Rheum"},{"key":"2902_CR37","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573\u20131576","journal-title":"J Rheumatol"},{"key":"2902_CR38","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Hoogen van den","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737\u20132747","journal-title":"Arthritis Rheum"},{"key":"2902_CR39","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/acr.20684","volume":"64","author":"SR Johnson","year":"2012","unstructured":"Johnson SR, Fransen J, Khanna D, Baron M, van den Hoogen F, Medsger TA Jr et al (2012) Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res 64:358\u2013367","journal-title":"Arthritis Care Res"},{"key":"2902_CR40","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1007\/s00296-011-2109-2","volume":"32","author":"S Pavlov-Dolijanovic","year":"2012","unstructured":"Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM, Vujasinovic Stupar NZ, Stanisavljevic DM (2012) Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud\u2019s phenomenon. Rheumatol Int 32:3039\u20133045","journal-title":"Rheumatol Int"},{"key":"2902_CR41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00005792-198011000-00001","volume":"59","author":"GP Rodnan","year":"1980","unstructured":"Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 59:393\u2013408","journal-title":"Medicine (Baltimore)"},{"key":"2902_CR42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/keu296","volume":"54","author":"C Bruni","year":"2015","unstructured":"Bruni C, Guiducci S, Bellando-Randone S, Lepri G, Braschi F, Fiori G et al (2015) Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. Rheumatology (Oxford) 54:72\u201376","journal-title":"Rheumatology (Oxford)"},{"key":"2902_CR43","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4236","volume":"15","author":"G Valentini","year":"2013","unstructured":"Valentini G, Marcoccia A, Cuomo G, Vettori S, Iudici M, Bondanini F et al (2013) Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther 15:R63","journal-title":"Arthritis Res Ther"},{"key":"2902_CR44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/rheumatology\/keq176","volume":"50","author":"G Valentini","year":"2011","unstructured":"Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A et al (2011) Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 50:317\u2013323","journal-title":"Rheumatology (Oxford)"},{"key":"2902_CR45","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-014-0037-0","volume":"34","author":"S Vettori","year":"2014","unstructured":"Vettori S, Cuomo G, Iudici M, D\u2019Abrosca V, Giacco V, Barra G et al (2014) Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol 34:663\u2013668","journal-title":"J Clin Immunol"},{"key":"2902_CR46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/annrheumdis-2012-202295","volume":"72","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S (2013) Very early versus early disease: the evolving definition of the \u2018many faces\u2019 of systemic sclerosis. Ann Rheum Dis 72:319\u2013321","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2902-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-015-2902-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2902-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:57:40Z","timestamp":1559120260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-015-2902-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,26]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["2902"],"URL":"https:\/\/doi.org\/10.1007\/s10067-015-2902-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,26]]}}}